Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 17/20 | 0.69 |
| ▸ | RARA | P10276 | 17/20 | 0.69 |
| ▸ | RARG | P13631 | 16/20 | 0.69 |
| ▸ | RXRA | P19793 | 2/20 | 0.60 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.60 |
| ▸ | CYP26B1 | Q9NR63 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10960163 | 0.87 | RARB (0.67) | RARBRARARARGRXRACYP26A1 | |
| SCHEMBL2331952 | 0.82 | RARB (1.00) | RARBRARARARGRXRACYP26A1 | |
| SCHEMBL9856398 | 0.79 | RARB (0.62) | RARBRARARARGRXRACYP26A1 | |
| SCHEMBL14003297 | 0.78 | RARG (0.71) | RARBRARARARG | |
| SCHEMBL30163074 | 0.78 | RARG (0.71) | RARBRARARARG | |
| SCHEMBL9374463 | 0.78 | RARA (0.90) | RARBRARARARGRXRACYP26A1 | |
| SCHEMBL10962664 | 0.78 | RARG (0.71) | RARBRARARARGRXRACYP26A1 | |
| SCHEMBL30590586 | 0.78 | RARG (0.71) | RARBRARARARGRXRACYP26A1 | |
| SCHEMBL9551739 | 0.77 | RARB (0.69) | RARBRARARARGRXRACYP26A1 | |
| SCHEMBL8656894 | 0.77 | RARG (0.71) | RARBRARARARGRXRACYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9421175-B2 | Prevention of retinopathy by inhibition of the visual cycle | LARSEN LARS MICHAEL (DK) | 2016-08-23 | — | — | US | disclosed |
| EP-1727529-B1 | PREVENTION OF RETINOPATHY BY INHIBITION OF THE VISUAL CYCLE | LARSEN LARS MICHAEL (DK) | 2016-03-02 | — | — | EP | disclosed |
| US-20080214668-A1 | USE OF RETINOIDS TO TREAT HIGH BLOOD PRESSURE AND OTHER CARDIOVASCULAR DISEASE | OREGON HEALTH AND SCIENCES UNIVERSITY (US) | 2008-09-04 | — | — | US | disclosed |
| US-20070249713-A1 | Prevention of Retinopathy by Inhibition of the Visual Cycle | LARSEN LARS M | 2007-10-25 | — | — | US | disclosed |
| EP-1727529-A2 | PREVENTION OF RETINOPATHY BY INHIBITION OF THE VISUAL CYCLE | Larsen, Lars, Michael (DK) | 2006-12-06 | — | — | EP | disclosed |
| WO-2005087210-A2 | PREVENTION OF RETINOPATHY BY INHIBITION OF THE VISUAL CYCLE | LARSEN LARS MICHAEL (DK) | 2005-09-22 | — | — | WO | disclosed |
| US-20030008919-A1 | Use of retinoids to treat high blood pressure and other cardiovascular disease | ROULLET JEAN-BAPTISTE (US) | 2003-01-09 | — | — | US | disclosed |
| US-6437003-B1 | STROKES | ROULLET JEAN-BAPTISTE (US) | 2002-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008919-A1 | Use of retinoids to treat high blood pressure and other cardiovascular disease | RARA, RXRA, RARB | RARB 3/4885RARA 1/4885RARG 5/4885 |
| US-20070249713-A1 | Prevention of Retinopathy by Inhibition of the Visual Cycle | VEGFA, HIF1AN, ALDH1A2 | RARB 74/4885RARA 121/4885RARG 44/4885 |
| US-20080214668-A1 | USE OF RETINOIDS TO TREAT HIGH BLOOD PRESSURE AND OTHER CARDIOVASCULAR DISEASE | RARA, RXRA, RARB | RARB 3/4885RARA 1/4885RARG 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.